Werewolf Therapeutics, Inc.

Informe acción NasdaqGS:HOWL

Capitalización de mercado: US$125.2m

Werewolf Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Werewolf Therapeutics' es Dan Hicklin , nombrado en Oct 2017, tiene una permanencia de 6.67 años. compensación anual total es $1.37M, compuesta por 42.7% salario y 57.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.49% de las acciones de la empresa, por valor de $2.03M. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 4.7 años, respectivamente.

Información clave

Dan Hicklin

Chief Executive Officer (CEO)

US$1.4m

Compensación total

Porcentaje del salario del CEO42.7%
Permanencia del CEO6.7yrs
Participación del CEO1.5%
Permanencia media de la dirección3.6yrs
Promedio de permanencia en la Junta Directiva4.7yrs

Actualizaciones recientes de la dirección

Recent updates

Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Jun 04
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 04

Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Feb 07
Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

Jan 19
Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Dec 09
There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Sep 30
Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 13
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

May 06
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Jan 27
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

Oct 24
We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Jul 08
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Mar 24
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Dec 09
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dan Hicklin en comparación con los beneficios de Werewolf Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

-US$42m

Dec 31 2023US$1mUS$583k

-US$37m

Sep 30 2023n/an/a

-US$37m

Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$2mUS$530k

-US$54m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$62m

Mar 31 2022n/an/a

-US$115m

Dec 31 2021US$2mUS$498k

-US$202m

Sep 30 2021n/an/a

-US$205m

Jun 30 2021n/an/a

-US$197m

Mar 31 2021n/an/a

-US$127m

Dec 31 2020US$3mUS$425k

-US$28m

Compensación vs. Mercado: La compensación total de Dan($USD1.37M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD673.68K).

Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.


CEO

Dan Hicklin (60 yo)

6.7yrs

Permanencia

US$1,366,904

Compensación

Dr. Daniel J. Hicklin, Ph D., also known as Dan, Founded Werewolf Therapeutics, Inc. in October 2017 and has been its President and Chief Executive Officer since August 2019. He serves on its Board of Dire...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Daniel Hicklin
Founder6.7yrsUS$1.37m1.49%
$ 1.9m
Timothy Trost
CFO, Treasurer & Assistant Secretary3.3yrsUS$815.59k0%
$ 0
Randi Isaacs
Chief Medical Officer3.6yrsUS$855.77k0%
$ 0
Chulani Karunatilake
Chief Technology Officer3yrsUS$3.86msin datos
Ellen Lubman
Chief Business Officer3.8yrssin datossin datos

3.6yrs

Permanencia media

64yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HOWL se considera experimentado (3.6 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Daniel Hicklin
Founder6.7yrsUS$1.37m1.49%
$ 1.9m
Luke Evnin
Independent Chairman of the Board6.7yrsUS$104.03k0%
$ 0
Michael Sherman
Independent Director3.1yrsUS$78.66k0%
$ 0
Charles Craik
Member of Scientific Advisory Boardno datasin datossin datos
Vijay Kuchroo
Member of Scientific Advisory Boardno datasin datossin datos
Briggs W. Morrison
Independent Director4.6yrsUS$62.32k0.036%
$ 44.7k
Karl Wittrup
Member of Scientific Advisory Boardno datasin datossin datos
Michael Atkins
Member of Scientific Advisory Board & Director5.8yrssin datos0.033%
$ 41.5k
Alon Lazarus
Independent Director4.8yrsUS$78.53k4.71%
$ 5.9m
Meeta Chatterjee
Independent Director2.7yrsUS$65.36k0%
$ 0
Derek DiRocco
Independent Director3.5yrsUS$72.53k0%
$ 0
Dario Vignali
Member of Scientific Advisory Boardno datasin datossin datos

4.7yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de HOWL se considera experimentada (4.7 años de antigüedad promedio).